UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2020

(Commission File No. 001-37518)

 

Benitec Biopharma Limited

(Translation of registrant’s name into English)

 

Level 14, 114 William St, Melbourne, VIC, 3000

Australia

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes      No  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes      No  

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes      No  

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit

 

Description

99.1

 

 

Nasdaq update

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

Benitec Biopharma Limited

 

By:

/s/ Megan Boston

Name:

Megan Boston

Title:

Executive Director

Date: April 3, 2020

 

 

bntc-ex99_6.htm

 

ASX/NASDAQ ANNOUNCEMENT

 

Benitec Biopharma Limited Announces Voluntary Delisting of American Depositary Shares and Warrants from the NASDAQ Capital Market in Connection with Its Redomiciliation to the United States

 

MELBOURNE, April 3, 2020 (GLOBE NEWSWIRE) – Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (“Benitec” or the “Company”) announces that formal notice was given by the Company to NASDAQ on April 2, 2020 (Pacific Time) of the intention to voluntarily delist the Company’s listed warrants from the NASDAQ Capital Market in connection with the completion of the scheme of arrangement to re-domicile the Benitec group from Australia to the United States of America (the “Scheme”).  

Additionally, as previously announced by the Company, upon the implementation of the Scheme, the American Depositary Shares (“ADSs”) of the Company will also be delisted from the NASDAQ Capital Market and be exchanged for shares of common stock of Benitec Biopharma Inc. (“Holdco”), a new U.S. company incorporated for the purpose of completing the re-domiciliation, which will be listed on the NASDAQ Capital Market under the ticker symbol “BNTC.”

The Company currently anticipates that it will file with the Securities and Exchange Commission (the “SEC”) a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) the Exchange Act, relating to the delisting and deregistration on or about April 14, 2020 (Pacific Time).  As a result, the Company expects that the last trading day of its ADSs and warrants on the NASDAQ Capital Market will be on or about April 14, 2020 (Pacific Time).  Further, the Company is expected to file a Form 15 with the SEC after the completion of the Scheme to terminate the registration of the ADSs and the warrants under Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

------ End -----

 


Benitec Biopharma Limited | Level 14, 114 William Street, Melbourne VIC 3000

t: +61 (03) 8692-7222 | e: info@benitec.com | www.benitec.com


 

Lodgement Authorisation

This announcement was authorised for lodgement with the ASX by the Benitec Disclosure Committee, pursuant to its Continuous Disclosure Policy.

 

About Benitec Biopharma Limited

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company focused on the development of novel genetic medicines. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Based in Melbourne, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B.

 

Safe Harbor Statement:

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in this ASX/Nasdaq announcement are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

 

Investor Relations

M Group Strategic Communications 

Jay Morakis

Managing Director

Tel: +1 646 859 5951

Email: jmorakis@MGroupSC.com

 

 

 

Benitec Biopharma Limited | Level 14, 114 William Street, Melbourne VIC 3000

t: +61 (03) 8692-7222 | e: info@benitec.com | www.benitec.com